{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:07:58Z","timestamp":1788516478733,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.vaccine.2023.07.037","type":"journal-article","created":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T10:54:04Z","timestamp":1690714444000},"page":"6456-6467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4331-5785","authenticated-orcid":false,"given":"Megan","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah G.","family":"Rosenblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle L.","family":"Moulia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R.","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom T.","family":"Shimabukuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona P.","family":"Havers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Dooling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Hadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia W.","family":"Gargano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.07.037_b0005","unstructured":"Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) GRADE (Grading of Recommendations, Assessment, Development and Evaluation); 2019 [cited 2023 January 4]; Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/index.html."},{"key":"10.1016\/j.vaccine.2023.07.037_b0010","unstructured":"Fink D. Emergency use authorization: overview and considerations for COVID-19 vaccines; 2020 [cited 2023 January 19]; Available from: https:\/\/www.fda.gov\/media\/144329\/download."},{"issue":"6","key":"10.1016\/j.vaccine.2023.07.037_b0015","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1473-3099(22)00054-8","article-title":"Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe","volume":"22","author":"Rosenblum","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.037_b0020","unstructured":"Centers for Disease Control and Prevention. Ensuring COVID-19 vaccine safety in the US; 2022 [cited 2023 January 4]; Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety.html."},{"key":"10.1016\/j.vaccine.2023.07.037_b0025","unstructured":"Lee GM. COVID-19 Vaccine Safety Technical (VaST) Subgroup; 2021 [cited 2023 January 11]; Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-01\/05-COVID-Lee-intro.pdf."},{"key":"10.1016\/j.vaccine.2023.07.037_b0030","unstructured":"University of Cambridge Winton Centre for Risk and Evidence Communication. Communicating the potential benefits and harms of the Astra-Zeneca COVID-19 Vaccine. 2021 [cited 2021 April 7]; Available from: https:\/\/wintoncentre.maths.cam.ac.uk\/news\/communicating-potential-benefits-and-harms-astra-zeneca-covid-19-vaccine\/."},{"key":"10.1016\/j.vaccine.2023.07.037_b0035","unstructured":"Australian Government. ATAGI statement on AstraZeneca vaccine in response to new vaccine safety concerns; 2021 [cited 2021 April 8]; Available from: https:\/\/www.health.gov.au\/news\/atagi-statement-on-astrazeneca-vaccine-in-response-to-new-vaccine-safety-concerns."},{"key":"10.1016\/j.vaccine.2023.07.037_b0040","unstructured":"Robert Koch Institute. 33 Epidemiologisches Bulletin; 2021 [cited 2021 August 19]; Available from: https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2021\/Ausgaben\/33_21.pdf?__blob=publicationFile."},{"key":"10.1016\/j.vaccine.2023.07.037_b0045","unstructured":"Australian Government. ATAGI statement on revised recommendations on the use of COVID-19 vaccine AstraZeneca;. 2021 [cited 2021 June 17]; Available from: https:\/\/www.health.gov.au\/news\/atagi-statement-on-revised-recommendations-on-the-use-of-covid-19-vaccine-astrazeneca-17-june-2021."},{"key":"10.1016\/j.vaccine.2023.07.037_b0050","unstructured":"Government of Canada. Archived 7: Recommendations on the use of COVID-19 vaccines; 2021 [cited 2021 April 23]; Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/recommendations-use-covid-19-vaccines\/april-23-2021.html."},{"key":"10.1016\/j.vaccine.2023.07.037_b0055","unstructured":"Government of Canada. Archived 9: Recommendations on the use of COVID-19 vaccines; 2021 [cited 2021 May 3]; Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/recommendations-use-covid-19-vaccines\/may-3-2021.html."},{"key":"10.1016\/j.vaccine.2023.07.037_b0060","unstructured":"Department of Health and Social Care. Independent report: JCVI statement on COVID-19 vaccination of children aged 12 to 15 years; 2021 [cited 2021 September 3]; Available from: https:\/\/www.gov.uk\/government\/publications\/jcvi-statement-september-2021-covid-19-vaccination-of-children-aged-12-to-15-years\/jcvi-statement-on-covid-19-vaccination-of-children-aged-12-to-15-years-3-september-2021."},{"issue":"19","key":"10.1016\/j.vaccine.2023.07.037_b0065","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.vaccine.2022.03.030","article-title":"Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16\u201329 years","volume":"40","author":"Funk","year":"2022","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.vaccine.2023.07.037_b0070","doi-asserted-by":"crossref","first-page":"651","DOI":"10.15585\/mmwr.mm7017e4","article-title":"Updated recommendations from the advisory committee on immunization practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients - United States, April 2021","volume":"70","author":"MacNeil","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.07.037_b0075","unstructured":"Centers for Disease Control and Prevention. COVID Data Tracker, COVID-NET Laboratory-confirmed COVID-19 hospitalizations; 2022 [cited 2022; Available from: https:\/\/covid.cdc.gov\/covid-data-tracker\/#covidnet-hospitalization-network."},{"key":"10.1016\/j.vaccine.2023.07.037_b0080","unstructured":"Centers for Disease Control and Prevention. COVID-19 Vaccination Data Systems and Data Sources; 2022 [cited 2022; Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/data-systems-sources.html."},{"key":"10.1016\/j.vaccine.2023.07.037_b0085","unstructured":"Centers for Disease Control and Prevention. National Population Projections: United States by Age, Gender, Ethnicity and Race for years 2014-2060, released by the U.S. Census Bureau on December 10, 2014, on CDC WONDER Online Database, 2015; 2021; Available from: http:\/\/wonder.cdc.gov\/population-projections-2014-2060.html."},{"key":"10.1016\/j.vaccine.2023.07.037_b0090","unstructured":"Centers for Disease Control and Prevention. Vaccine Adverse Event Reporting System (VAERS) Standard Operating Procedures for COVID-19 2022 [cited 2023 January 5]; Available from: https:\/\/www.cdc.gov\/vaccinesafety\/pdf\/VAERS-COVID19-SOP-02-02-2022-508.pdf."},{"key":"10.1016\/j.vaccine.2023.07.037_b0095","unstructured":"Centers for Disease Control and Prevention and Food and Drug Administration. Vaccine Adverse Event Reporting System; 2022 [cited 2022 November 11]; Available from: https:\/\/vaers.hhs.gov\/."},{"key":"10.1016\/j.vaccine.2023.07.037_b0100","unstructured":"U.S. Food and Drug Administration. COVID-19 Vaccines; 2022 [cited 2023 January 3]; Available from: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/covid-19-vaccines."},{"key":"10.1016\/j.vaccine.2023.07.037_b0105","unstructured":"Centers for Disease Control and Prevention. Vaccine Safety Datalink (VSD). 2022 [cited 2022 November 11]; Available from: https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/vsd\/index.html."},{"key":"10.1016\/j.vaccine.2023.07.037_b0110","unstructured":"Centers for Disease Control and Prevention. Rapid Cycle Analysis (RCA) to monitor the safety of COVID-19 vaccines in near real-time within the Vaccine Safety Datalink; 2021 [cited 2022 January 5]; Available from: https:\/\/www.cdc.gov\/vaccinesafety\/pdf\/COVID-19-RCA-Protocol-Summary-2021_508.pdf."},{"key":"10.1016\/j.vaccine.2023.07.037_b0115","unstructured":"Centers for Disease Control and Prevention. ACIP Meeting Information; 2022 [cited 2022 December 8]; Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/index.html."},{"key":"10.1016\/j.vaccine.2023.07.037_b0120","unstructured":"Centers for Disease Control and Prevention, Cases of cerebral venous sinus thrombosis with thrombocytopenia after receipt of the Johnson & Johnson COVID-19 vaccine. H.A.N. (HAN), Editor; 2021, US Department of Health and Human Services, CDC: Atlanta, GA."},{"key":"10.1016\/j.vaccine.2023.07.037_b0125","unstructured":"Marks P, Schuchat A. Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine; 2021 [cited 2023 January 5]; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine."},{"issue":"5","key":"10.1016\/j.vaccine.2023.07.037_b0130","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.vaccine.2023.07.037_b0135","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.vaccine.2023.07.037_b0140","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.037_b0145","doi-asserted-by":"crossref","unstructured":"Havers FP, et al. COVID-19-associated hospitalizations among vaccinated and unvaccinated adults \u226518 years \u2013 COVID-NET, 13 states, January 1 \u2013 July 24, 2021. medRxiv 2021: p. 2021.08.27.21262356.","DOI":"10.1101\/2021.08.27.21262356"},{"issue":"5152","key":"10.1016\/j.vaccine.2023.07.037_b0150","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.15585\/mmwr.mm695152e2","article-title":"The advisory committee on immunization practices' updated interim recommendation for allocation of COVID-19 vaccine - United States, December 2020","volume":"69","author":"Dooling","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"10.1016\/j.vaccine.2023.07.037_b0155","doi-asserted-by":"crossref","first-page":"329","DOI":"10.15585\/mmwr.mm7009e4","article-title":"The advisory committee on immunization practices' interim recommendation for use of Janssen COVID-19 vaccine - United States, February 2021","volume":"70","author":"Oliver","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.07.037_b0160","unstructured":"Oliver SE. Thrombosis with thrombocytopenic syndrome (TTS) after COVID-19 vaccines: Applying the Evidence to Recommendation Framework. 2021 [cited 2021 April 23]; Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-04-23\/06-COVID-Oliver-508.pdf."},{"key":"10.1016\/j.vaccine.2023.07.037_b0165","unstructured":"Centers for Disease Control and Prevention. COVID-19 VaST Work Group Report \u2013 May 17, 2021. 2021 [cited 2023 January 5]; Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/work-groups-vast\/report-2021-05-17.html."},{"issue":"4","key":"10.1016\/j.vaccine.2023.07.037_b0170","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US From December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"issue":"27","key":"10.1016\/j.vaccine.2023.07.037_b0175","doi-asserted-by":"crossref","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","article-title":"Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices - United States, June 2021","volume":"70","author":"Gargano","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.07.037_b0180","unstructured":"Centers for Disease Control and Prevention. COVID-19 Weekly Cases per 100,000 Population by Age; 2022 [CDC unpublished data]."},{"key":"10.1016\/j.vaccine.2023.07.037_b0185","unstructured":"Pilishvili T, et al. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel - 33 U.S. Sites, January-March 2021. MMWR Morb Mortal Wkly Rep 2021; 70(20): p. 753-758."},{"issue":"18","key":"10.1016\/j.vaccine.2023.07.037_b0190","doi-asserted-by":"crossref","first-page":"674","DOI":"10.15585\/mmwr.mm7018e1","article-title":"Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged >\/=65 years - United States, January-March 2021","volume":"70","author":"Tenforde","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.07.037_b0195","unstructured":"Wallace M. COVID-19 mRNA vaccines in adolescents and young adults: benefit-risk discussion; 2021 [cited 2021 June 23]; Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-06\/05-COVID-Wallace-508.pdf."},{"key":"10.1016\/j.vaccine.2023.07.037_b0200","doi-asserted-by":"crossref","unstructured":"Woo EJ, et al. Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barre syndrome, February-July 2021. JAMA 2021; 326(16): 1606\u20131613.","DOI":"10.1001\/jama.2021.16496"},{"issue":"32","key":"10.1016\/j.vaccine.2023.07.037_b0205","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.15585\/mmwr.mm7032e4","article-title":"Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the advisory committee on immunization practices - United States, July 2021","volume":"70","author":"Rosenblum","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.07.037_b0210","unstructured":"Rosenblum HG. Benefit-risk discussion for use of Pfizer-BioNTech COVID-19 vaccine in individuals \u226516 years of age; 2021; Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-08-30\/06-COVID-Rosenblum-508.pdf."},{"issue":"12","key":"10.1016\/j.vaccine.2023.07.037_b0215","doi-asserted-by":"crossref","first-page":"e0278624","DOI":"10.1371\/journal.pone.0278624","article-title":"Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: A rapid systematic review and meta-analysis of non-randomized studies","volume":"17","author":"Wallace","year":"2022","journal-title":"PLoS One"},{"issue":"38","key":"10.1016\/j.vaccine.2023.07.037_b0220","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.15585\/mmwr.mm7038e2","article-title":"Use of Pfizer-BioNTech COVID-19 vaccine in persons aged >\/=16 years: recommendations of the advisory committee on immunization practices - United States, September 2021","volume":"70","author":"Dooling","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.07.037_b0225","doi-asserted-by":"crossref","unstructured":"Scobie HM, et al. Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status - 13 U.S. Jurisdictions, April 4-July 17, 2021. MMWR Morb Mortal Wkly Rep 2021; 70(37): 1284\u20131290.","DOI":"10.15585\/mmwr.mm7037e1"},{"issue":"6","key":"10.1016\/j.vaccine.2023.07.037_b0230","first-page":"1055","article-title":"Field evaluation of vaccine efficacy","volume":"63","author":"Orenstein","year":"1985","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2023.07.037_b0235","doi-asserted-by":"crossref","unstructured":"Grannis SJ, et al. Interim estimates of COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance - Nine States, June-August 2021. MMWR Morb Mortal Wkly Rep 2021; 70(37): 1291\u20131293.","DOI":"10.15585\/mmwr.mm7037e2"},{"issue":"34","key":"10.1016\/j.vaccine.2023.07.037_b0240","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.15585\/mmwr.mm7034e2","article-title":"Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults - United States, March-July 2021","volume":"70","author":"Tenforde","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"10.1016\/j.vaccine.2023.07.037_b0245","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jamainternmed.2022.4299","article-title":"COVID-19-associated hospitalizations among vaccinated and unvaccinated adults 18 years or older in 13 US States, January 2021 to April 2022","volume":"182","author":"Havers","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"44","key":"10.1016\/j.vaccine.2023.07.037_b0250","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.15585\/mmwr.mm7044e2","article-title":"The advisory committee on immunization practices' interim recommendations for additional primary and booster doses of COVID-19 vaccines - United States, 2021","volume":"70","author":"Mbaeyi","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"15","key":"10.1016\/j.vaccine.2023.07.037_b0255","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.037_b0260","unstructured":"Wallace M. COVID-19 vaccine booster doses: Benefit\/risk discussion; 2021 [cited 2021 September 23]; Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-9-23\/02-COVID-Wallace-508.pdf."},{"key":"10.1016\/j.vaccine.2023.07.037_b0265","unstructured":"Dooling K. Evidence to recommendations; 2021 [cited 2021 October 21]; Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-10-20-21\/11-COVID-Dooling-508.pdf."},{"key":"10.1016\/j.vaccine.2023.07.037_b0270","unstructured":"Walensky R. CDC expands COVID-19 booster recommendations 2021, Centers for Disease Control and Prevenation, U.S. Department of Health and Human Services: Atlanta, GA."},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.037_b0275","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age","volume":"386","author":"Walter","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.037_b0280","unstructured":"Oliver SE. Evidence to recommendations framework: Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years; 2021 [cited 2021 November 2]; Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-11-2-3\/08-COVID-Oliver-508.pdf."},{"issue":"45","key":"10.1016\/j.vaccine.2023.07.037_b0285","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.15585\/mmwr.mm7045e1","article-title":"The advisory committee on immunization practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in children aged 5\u201311 years - United States, November 2021","volume":"70","author":"Woodworth","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.07.037_b0290","unstructured":"Centers for Disease Control and Prevention. COVID-NET rates of laboratory-confirmed COVID-19 hospitalizations by vaccination status; 2022 [unpublished CDC data]."},{"issue":"38","key":"10.1016\/j.vaccine.2023.07.037_b0295","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15585\/mmwr.mm7038e1","article-title":"Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions - United States, March-August 2021","volume":"70","author":"Self","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2023.07.037_b0300","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M21-4502","article-title":"Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021","volume":"175","author":"See","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2023.07.037_b0305","unstructured":"Oliver SE. Updates to the benefit\/risk assessment for Janssen COVID-19 vaccines: Applying the Evidence to Recommendation Framework; 2021 [cited 2021 December 16]; Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-12-16\/04_COVID_Oliver_2021-12-16.pdf."},{"issue":"3","key":"10.1016\/j.vaccine.2023.07.037_b0310","doi-asserted-by":"crossref","first-page":"90","DOI":"10.15585\/mmwr.mm7103a4","article-title":"Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021","volume":"71","author":"Oliver","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.07.037_b0315","unstructured":"COVID-19 Scenario Modeling Hub. Model Projection; 2021; Available from: https:\/\/covid19scenariomodelinghub.org\/viz.html."},{"issue":"36","key":"10.1016\/j.vaccine.2023.07.037_b0320","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2023.07.037_b0325","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2300868X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2300868X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T17:06:31Z","timestamp":1736442391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2300868X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":65,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0264410X2300868X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}